Pacific Edge hopes it can avoid another capital raising
Sales from any one of four key potential US customers could result in a quantum leap in revenue.
Pacific Edge says it has enough cash to continuing operating at its cost base for another 15 months and hopes to secure sufficient sales to break even before that cash runs out.
The company, which has developed tests to detect and monitor bladder cancer, reported an $11.3 million net loss for
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Jenny Ruth
Fri, 25 Nov 2016
Fri, 25 Nov 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Pacific Edge hopes it can avoid another capital raising
63395